Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Adaptive Biotechnologies Chief Commercial Officer Sharon Benzeno sold 63,103 shares on March 11, 2026, for $13.17 per share, totaling $831,066. The sale was executed to meet tax withholding obligations tied to vesting restricted stock units under the company’s equity incentive plans. The transaction occurs after a recent 11% slide in the stock over…
Director Neil Mehta filed purchases of 7,350,104 Coupang Class A shares valued at $136.5 million in three transactions reported on a Form 4 with the SEC. The buys took place March 11-13, 2026, and follow a roughly 43% decline in the stock over the prior six months. The company reported Q4 2025 results that missed revenue and EPS expectations and dr…
Adaptive Biotechnologies executive Francis Lo sold 30,593 shares on March 11, 2026, for $430,749 under a Rule 10b5-1 plan. The transaction leaves Lo with 291,374 directly held shares and 2,500 indirectly held through a spouse. The stock has shown short-term weakness but strong one-year gains, while the company reported Q4 2025 results that beat est…
Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of company stock on March 11, 2026, for roughly $6.19 million. The two transactions were executed at $13.17 per share and were mandated by the company to satisfy tax withholding tied to vested restricted stock units and performance share units. The stock…
Nias James, chief accounting officer at nLIGHT, sold 1,808 shares on March 12, 2026, for a total of $116,471 under a pre-established Rule 10b5-1 plan. The disposition took place while the stock traded close to its 52-week peak following a year of substantial gains. Recent quarterly results and analyst price-target increases have highlighted the com…
Adaptive Biotechnologies Chief Executive Officer and Chairman Chad M. Robins completed two mandated sales of company shares on March 11, 2026, totaling 470,167 shares at $13.17 each, equal to roughly $6.19 million. The filings disclose the sales were to satisfy tax withholding obligations from vested restricted stock and performance share units and…
nLIGHT, Inc. director Raymond A. Link sold 25,404 shares of common stock between March 11 and March 13, 2026, for roughly $1.6 million under a Rule 10b5-1 plan adopted in December 2025. The transactions occurred while the stock traded close to its 52-week high following substantial year-over-year gains and better-than-expected fourth-quarter result…
Simrat Randhawa, Executive Vice President and Head of R&D at Dianthus Therapeutics, sold 33,830 shares for $2,756,468 and exercised options to acquire the same number of shares on March 12, 2026. The activity took place as the company completed a major public offering that raised about $719 million and after several analyst firms raised price targe…
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, sold 43,682 shares of the company’s common stock on March 12, 2026, generating about $3.56 million. On the same day he exercised options to acquire an equal number of shares at exercise prices between $17.88 and $22.07. The transactions take place as Dianthus stock has climbed sharply …
Symbotic Inc. director Saintil Merline filed a Form 4 showing two planned sales on March 11, 2026 that disposed of 3,414 shares of Class A common stock for about $173,483. The transactions occurred under a pre-arranged trading plan. The insider sale comes as the stock trades below the sale prices while the company reports mixed quarterly results an…
Crexendo Chief Strategy Officer Anand Buch sold 88,000 shares across two transactions on March 11 and March 13, 2026, according to a Form 4 filing, generating $579,200. The company reported fourth-quarter 2025 earnings that beat EPS expectations while revenue fell marginally short of estimates, and announced an acquisition of ESI that prompted Need…
Alpha Metallurgical Resources director Kenneth S. Courtis bought 10,000 shares on March 11, 2026, spending $1.8 million at prices between $185.28 and $187.87. The insider purchases come as the company reported a disappointing Q4 2025 with EPS and revenue misses, and as analysts kept Hold ratings while trimming price targets.
Kurt L. Kalbfleisch, CEO and CFO of Sphere 3D Corp (NASDAQ: ANY), sold 9,800 shares on March 13, 2026 for $1.59 per share, netting $15,582. The sale came one day after he exercised restricted stock units to acquire 18,358 shares. The company has recently regained Nasdaq minimum bid-price compliance, approved corporate governance measures at a speci…
Tiah Norton Reppas, Chief Accounting Officer of Sphere 3D Corp (NASDAQ: ANY), sold 6,250 shares on March 12, 2026 for $1.61 per share, totaling $10,062. The transaction followed an exercise of restricted stock units the day before and comes as the company reports regained Nasdaq minimum bid price compliance, a 1-for-10 reverse stock split, and shar…
Apogee Therapeutics CEO Michael Thomas Henderson sold 19,990 shares of company stock on March 11, 2026, under a Rule 10b5-1 plan adopted in August 2025. The trades, executed at prices between $74.29 and $75.86, reduced Henderson's direct holdings to 1,152,987 shares. The sale occurs amid strong share gains over the past year and a mix of analyst re…
Texas Roadhouse Chief Technology Officer Hernan E. Mujica sold 5,000 shares on March 13, 2026, for roughly $850,000. The transaction comes after the company reported fourth-quarter 2025 earnings that missed expectations, prompting mixed analyst revisions driven by beef inflation, weather disruptions and labor inefficiencies.
Fox Corporation Executive Chair and CEO Lachlan Murdoch executed a series of stock sales of Class A Common Stock between March 11 and March 13, 2026, totaling approximately $65.4 million. The transactions, disclosed on a Form 4, include multiple block sales, an exchange with the LKM Family Trust, and option exercises. The activity occurred while Fo…
John Nallen, President and Chief Operating Officer of Fox Corporation, disposed of $26.5 million in Class A Common Stock across multiple trades on March 11 and 12, 2026, while simultaneously exercising options to acquire 459,115 shares. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted December 2, 2025. Fox reported a…
Sarepta Therapeutics director Stephen Mayo sold 7,239 shares of common stock on March 12, 2026, at $17.02 per share for $123,207 to satisfy tax obligations arising from vested restricted stock units. The transaction leaves Mayo with 1,765 shares directly held. Sarepta shares were trading near $16.40, a decline of 84% from their 52-week high of $103…
Confluent, Inc. Chief Financial Officer Sivaram Rohan sold 29,996 Class A shares on March 12, 2026, generating about $919,977. The disposition, carried out under a 10b5-1 trading plan established in December 2025, leaves Rohan with 531,971 shares. The move comes while Confluent stock trades close to its 52-week peak amid strong six-month performanc…
Andrew M. Cohn, a director at Global Water Resources, Inc. (NASDAQ:GWRS), made two recent purchases of company common stock in March 2026, including an $131,796 acquisition. The transactions leave Cohn with more than 2.56 million shares directly and 42,150 indirectly. The moves coincide with the stock trading near its 52-week low and follow recent …
Maria Georgia Magno, Chief Legal Officer at Baker Hughes Co (BKR), sold 5,063 Class A shares on March 11, 2026, under a previously established Rule 10b5-1 plan. The transaction totaled $298,919. After the sale Magno holds 15,555.296 shares. The company has recently issued $9.5 billion of debt to finance the Chart Industries acquisition and secured …
Framework Ventures IV L.P. bought 29,494 shares of Better Home & Finance Holding Co. (NASDAQ: BETR) on March 13, 2026, at $34.12 per share for a total of $1,006,335, raising its direct holdings to 834,312 shares. The transaction sits alongside the company’s reported strong fourth-quarter 2025 results and management commentary pointing to progress o…
Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals (LGND), sold 3,057 shares on March 11, 2026, for $225.00 per share, realizing $687,825. He also exercised options for 2,405 shares at $92.65, a transaction valued at $222,823. The moves were carried out under a trading plan adopted November 19, 2025; after the sale Espinoza directl…
Jarvis Scot B., a director at Kratos Defense & Security Solutions (KTOS), sold 5,000 shares on March 12, 2026, for $88.6 per share, generating $443,000. The transaction, carried out under a pre-existing 10b5-1 plan adopted September 15, 2025, leaves Jarvis with 85,417 shares. The sale occurs alongside several corporate developments including a $7 m…
